Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13562313 | 0.92 | HRH4 (0.59) | HRH4HRH3 | |
| SCHEMBL13562345 | 0.81 | HRH4 (0.94) | HRH4HRH3 | |
| SCHEMBL10263654 | 0.80 | HRH4 (0.67) | HRH4HRH3 | |
| SCHEMBL10263380 | 0.78 | HRH4 (1.00) | HRH4HRH3 | |
| SCHEMBL13804459 | 0.77 | GRIN2D (0.40) | HRH4 | |
| SCHEMBL13562344 | 0.77 | HRH4 (0.97) | HRH4HRH3 | |
| SCHEMBL10264407 | 0.77 | HRH4 (0.49) | HRH4HRH3 | |
| SCHEMBL4123765 | 0.77 | ALOX15 (0.45) | — | |
| SCHEMBL10262912 | 0.73 | HRH4 (0.62) | HRH4HRH3 | |
| SCHEMBL10263608 | 0.73 | HRH4 (0.61) | HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120277238-A1 | PHARMACEUTICAL COMPOSITION CONTAINING FUSED HETERO-RING DERIVATIVE | SHIONOGI & CO., LTD (JP) | 2012-11-01 | — | — | US | disclosed |
| US-20120277238-A1 | PHARMACEUTICAL COMPOSITION CONTAINING FUSED HETERO-RING DERIVATIVE | SHIONOGI & CO., LTD (JP) | 2012-11-01 | — | — | US | disclosed |
| EP-2460794-A1 | PHARMACEUTICAL COMPOSITION CONTAINING FUSED HETERO-RING DERIVATIVE | Shionogi & Co., Ltd. (JP) | 2012-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277238-A1 | PHARMACEUTICAL COMPOSITION CONTAINING FUSED HETERO-RING DERIVATIVE | HRH4, HRH3, HRH2 | HRH4 1/4885HRH3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.